FDA clears IRIS's (International Remote Imaging Systems) urinalysis system:
This article was originally published in Clinica
International Remote Imaging Systems (IRIS) has received FDA 510(k) clearance to market its automated 939UDx urine pathology system in the US. Chatsworth, California-based IRIS claimed that the product is the first "full-walkaway" system that can perform complete urinalysis profiles with automatic reporting of microscopic sediment results for most specimens. The system, which was launched at the beginning of May, integrates the Roche Hitachi Chemstrip Super UA urine analyser for urine test strip chemistries with IRIS's imaging flow cytometer and a high-resolution image display station.
You may also be interested in...
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.